Society for Participatory Medicine
FEBRUARY 1, 2023
By the power vested in clinical research, the FDA now pronounces us patient and industry. The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. I’m here to deliver some great news: we tied the knot!
Digital Health Global
MARCH 26, 2024
Indivi is dedicated to unlocking the immense potential of digital biomarkers in drug development and healthcare by creating a unique symbiotic intersection between expert knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and artificial intelligence).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
MARCH 2, 2023
Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
Healthcare IT Today
JANUARY 8, 2024
The excitement around new tools took hold of all industries in 2023, and the potential is expansive. The unification of technology, services and pharmacovigilance expertise in the coming year will further enunciate the industry’s focus on patient safety. Dave Latshaw, CEO at BioPhy 1. Dave Latshaw, CEO at BioPhy 1.
Digital Health Global
JUNE 13, 2023
We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. Koneksa’s extensive commitment to research includes the potential for industry participation in studies.
Society for Participatory Medicine
JANUARY 27, 2022
The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care. Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users.
Digital Health Global
SEPTEMBER 27, 2023
About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. ALSP’s portfolio companies are backed by renowned life science investors and are comprised of industry-leading, transformative companies, including KayoThera, Inc.,
Expert insights. Personalized for you.
144 
Let's personalize your content